BAVARIAN NORDIC
Bavarian Nordic is a industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases.
BAVARIAN NORDIC
Industry:
Biotechnology Health Care Medical
Founded:
1994-01-01
Address:
Kvistgaard, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.bavarian-nordic.com
Total Employee:
251+
Status:
Active
Contact:
(453) 326-8383
Email Addresses:
[email protected]
Total Funding:
328.76 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Domain Not Resolving SSL By Default Google Tag Manager Euro Google Analytics HSTS Google Maps
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Novatreat
Novatreat is a biotechnology firm, specializes in developing and producing novel immune milk products for the treatment.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Vital Therapies
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Current Advisors List
Current Employees Featured
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2023-02-15 | Emergent BioSolutions - Travel Health Business | Emergent BioSolutions - Travel Health Business acquired by Bavarian Nordic | 274 M USD |
2009-11-11 | BN ImmunoTherapeutics | BN ImmunoTherapeutics acquired by Bavarian Nordic | N/A |
Investors List
European Investment Bank
European Investment Bank investment in Post-IPO Debt - Bavarian Nordic
National Institutes of Health
National Institutes of Health investment in Grant - Bavarian Nordic
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2016-11-26 | Nabobil.no | Bavarian Nordic investment in Corporate Round - Nabobil.no | 5 M NOK |
Key Employee Changes
Date | New article |
---|---|
2022-01-19 | Bavarian Nordic Appoints Russell Thirsk as new Chief Operating Officer |
Official Site Inspections
http://www.bavarian-nordic.com Semrush global rank: 1.66 M Semrush visits lastest month: 13.97 K
- Host name: web1.scannet.dk
- IP address: 46.36.210.3
- Location: Randers Denmark
- Latitude: 56.4893
- Longitude: 10.262
- Timezone: Europe/Copenhagen
- Postal: 8900
More informations about "Bavarian Nordic"
Bavarian Nordic - Wikipedia
Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus [de] near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany and San Diego, CโฆSee details»
Annual Report 2023 Protecting our tomorrow - Bavarian Nordic
Bavarian Nordic, and we aspire to develop vaccines that address unmet medical needs for the greater good of the global society. A pioneering force in vaccines ... acquisitions and โฆSee details»
Bavarian Nordic - Crunchbase Company Profile
Bavarian Nordic is a industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in โฆSee details»
USA - About Bavarian Nordic
Bavarian Nordic is committed to the prevention of infectious diseases through innovation in the development, manufacture and supply of life-saving vaccines. ... World Health Organization. โฆSee details»
Home | USA | Bavarian Nordic
Bavarian nordic Bavarian Nordic is a global vaccines company on a mission to help improve and protect lives through innovative vaccines. With 30 years of excellence in vaccine development and manufacturing, our purpose is driven โฆSee details»
Bavarian Nordic
Bavarian Nordic - a pioneering force in vaccines โ expanding our reach and impact through life-changing solutions. OUR LOCATIONS . Hellerup, Denmark (Headquarters) Kvistgård, Denmark (Manufacturing) Hørsholm, Denmark โฆSee details»
Our work in infectious disease vaccines - Bavarian Nordic
To protect the citizens of the US, Canada and Europe, Bavarian Nordic produces a smallpox vaccine for secure national stockpiles. We provided 28 million doses of our vaccine to the US for emergency use in counter bioterrorism efforts. ...See details»
Sustainability - Bavarian Nordic
In Bavarian Nordic, we contribute to the society by developing and manufacturing vaccines that provide protection against deadly diseases. While seeking to create a growing, sustainable โฆSee details»
Bavarian Nordic, Other Health Stocks Jump on Mpox Concerns
Aug 15, 2024 Bavarian Nordic, one of the few companies with an approved mpox vaccine, soared as much as 17% in Denmark to the highest intraday level since November 2022. โฆSee details»
Bavarian Nordic A/S | Reuters
Nov 18, 2024 The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially โฆSee details»
Bavarian Nordicโs Big Rally Just the Latest in Volatile History
Aug 28, 2024 Bavarian Nordic shares surged 54% in July 2022, when the head of the World Health Organization declared the outbreak of mpox โ then called monkeypox โ a public โฆSee details»
WHO Prequalifies Bavarian Nordicโs MVA-BN as First Vaccine โฆ
On September 13, 2024, the World Health Organization (WHO) announced that it added the first vaccine against monkeypox (mpox) to its prequalification list. The vaccine, MVA-BN, is โฆSee details»
WHO grants approval for use of Bavarian Nordicโs mpox vaccine in ...
On 8 October 2024, WHO granted prequalification for the age-extension of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine for use in adolescents aged 12 to 17 years, โฆSee details»
Annual Report 2019 - Bavarian Nordic
Indication for monkeypox also establishes Bavarian Nordic as a leader in this field, offering a new, exciting commercial opportunity for Bavarian Nordic. HIGHLIGHTS FROM 2019 2019 marked โฆSee details»
Nordnet om Bavarian Nordic: Investorer risikerer at blive skuffede
Nov 25, 2024 Bavarian Nordic ser ud til at stå foran et potentielt rekordår i 2025, men risikoen for skuffelser lurer på længere sigt.. Sådan lyder advarslen fra Nordnets investeringsøkonom, โฆSee details»
Bavarian Nordic legt weiter zu โ gelingt jetzt der Turnaround?
Nov 25, 2024 Die Aktie von Bavarian Nordic hat im August dieses Jahres bei 42,77 Euro ein neues Hoch markieren können. Danach ist dem Papier allerdings die Luft ausgegangen und โฆSee details»
Sustainability Report 2023 Protecting our tomorrow - Bavarian โฆ
Introduction Bavarian Nordic Sustainability Report 2023 3 Our Purpose Protecting lives every day is an essential part of our DNA in Bavarian Nordic, and we develop and supply vaccines that โฆSee details»
Kapitalforhøjelse i Bavarian Nordic A/S som følge af โฆ
Nov 29, 2024 De nye aktier, der oppebærer samme rettigheder i enhver henseende som eksisterende Bavarian Nordic-aktier, vil blive optaget til handel og officiel notering på Nasdaq โฆSee details»
Bavarian Nordic, France
Bavarian Nordic France SAS 27 avenue de l'Opéra 75001 PARIS. Land line phone number (when available) Declarer une reclamation qualite produit (Products Quality complaints reporting) โฆSee details»
Bavarian Nordic
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: โ2015 was another great year for Bavarian Nordic, which is highlighted by the strong progress made in all our key โฆSee details»